Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil takes first concrete step in assessing the economic impact of regulation

This article was originally published in Clinica

Executive Summary

The heads of Brazilian healthcare regulatory agency Anvisa are close to receiving a draft framework for the first national assessment of the economic impact of its activities. The group set up to draft the project is expected to report to Anvisa's directorate by the end of this month, according to a statement issued by Anvisa following a conference involving consultants on the project, held on August 11, in Brasilia. This is the first stage in a wider programme to assess the impact of regulation across all industrial sectors, which Anvisa was chosen to pilot (see Clinica No 1318, p 2).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel